AW
VKTX icon

Avion Wealth’s Viking Therapeutics VKTX Stock Holding History

Avion Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Hold
121
– – ﹤0.01% 887
2026
Q1 		$3K Hold
121
– – ﹤0.01% 822
2025
Q4 		$4K Sell
121
-1,400
-92% -$49.6K ﹤0.01% 747
2025
Q3 		$39K Buy
1,521
+1,400
+1,157% +$41.8K 0.01% 248
2025
Q2 		$3K Buy
121
+21
+21% +$553 ﹤0.01% 761
2025
Q1 		$4K Hold
100
– – ﹤0.01% 610
2024
Q4 		$4K Buy
+100
New +$5.7K ﹤0.01% 608
2024
Q3 		– Sell
-10
Closed – – 1346
2024
Q2 		$0 Buy
+10
New +$656 ﹤0.01% 1267

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Avion Wealth's VKTX Position: Q2 2026 in Review

Avion Wealth held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 121 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Avion Wealth first reported a position in VKTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $39K in Q3 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Avion Wealth held 121 shares of Viking Therapeutics worth $4K as of Q2 2026.
  • Avion Wealth left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #887 holding.
  • Avion Wealth first reported a position in Viking Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Avion Wealth's Viking Therapeutics position peaked at $39K in Q3 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.